Filing Flows › Supernus Pharmaceuticals (SUPN) › Q1 2026
Supernus Pharmaceuticals (SUPN) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Supernus Pharmaceuticals (SUPN) reported revenue of $208M for the first quarter 2026 (Q1 2026), +39% from a year earlier and -2% from the quarter before. Operating margin was -4.0%, net loss $2.3M (1.1% of revenue).
Supernus Pharmaceuticals, Q1 2026: revenue $208M (+39% year over year), operating margin -4.0%, net loss $2.3M, operating cash flow $66.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $208M | -2% | +39% |
| Operating profit | −$8.3M | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | $66.5M | +235% | +117% |
What changed
Revenue was $207.7M in Q1 2026, up 39% year over year and down 2% from the previous quarter. Qelbree was the largest line at 37% of revenue. Royalty, licensing, and other revenues added $21.5M year over year (up 274%), 37% of the total change. APOKYN declined 48%.
Operating costs exceeded revenue by $8.3M, an operating margin of -4.0%. Total costs grew 35% against revenue growth of 39%. The fastest-growing cost line was Cost of revenue (+48%). The quarter ended with a net loss of $2.3M, narrower than the previous quarter's $4.1M loss. Non-operating items added $2.4M, -40% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $66.5M (up 117% year over year). Non-cash charges added back $26.1M of depreciation and amortization and $8.5M of share-based compensation. Working capital and other items added $34.2M.
Questions
What was Supernus Pharmaceuticals' revenue in the first quarter 2026?
Supernus Pharmaceuticals (SUPN) reported revenue of $208M for the first quarter 2026 (Q1 2026), +39% from a year earlier and -2% from the quarter before.
Was Supernus Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $8.3M (-4.0% of revenue) and net loss $2.3M.